Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-DOTA-MHC-II
- Development stage
- Preclinical
- Lead developer
- Houston Methodist Academic Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
64Cu-DOTA-MHC-II (also referred to as 64Cu-DOTA-MHCII) is an experimental, preclinical immuno-PET radiotracer designed for noninvasive imaging of tumor-specific major histocompatibility complex class II (tsMHC-II) expression. It is composed of a monoclonal antibody targeting MHC-II conjugated to the chelator DOTA and radiolabeled with the positron-emitting isotope copper-64 (64Cu). Developed by academic researchers at the Houston Methodist Academic Institute and collaborating institutions, the tracer has been evaluated in murine melanoma models (such as B16F10 and B16SIY) to monitor dynamic changes in tsMHC-II expression following interferon-gamma (IFNγ) stimulation or anti-PD-1 immunotherapy. This imaging approach aims to predict response to immune checkpoint inhibitors and distinguish immune-responder tumors from nonresponders.
- Other names
- 64Cu-DOTA-MHCII64Cu-DOTA-conjugated anti-MHC-II antibody64Cu-DOTA-conjugated MHC-II antibody64Cu-labeled anti-MHC-II antibody64Cu-labeled MHC-II antibody[64Cu]Cu-DOTA-MHCII
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on 64Cu-DOTA-MHC-II.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-DOTA-MHC-II.